Drug intelligence / Profile preview

BGA012

Development stage: Preclinical
Lead developer: Biogenera
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

BGA012 is a preclinical-stage anti-gene peptide nucleic acid (Ag-PNA) oligonucleotide developed by Biogenera for the treatment of metabolic disorders. The drug utilizes Biogenera's proprietary Ag-PNA platform, which involves synthetic DNA/RNA mimics with a pseudo-peptide backbone designed to bind with high affinity to specific genomic DNA sequences. This binding aims to block the transcription of a confidential target gene associated with metabolic dysfunction. As of 2024, the program remains in the preclinical phase of development.

Targets

DNA

Beyond the preview

Go deeper on BGA012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGA012.

Explore the full profile